Characterization of Macroprolactinemia

This study has been completed.

Sponsor:

Information provided by:

Kansai Medical University

ClinicalTrials.gov Identifier:

NCT00436111

First received: February 15, 2007

Last updated: NA

Last verified: February 2007

History: No changes posted

Purpose

The purpose of this study is to clarify the nature of macroprolactin which has recently been highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia. The results of this study are beneficial for the patients to whom unnecessary medications and unnecessary radiological examinations have been performed.

We used the remained serum samples taken for routine prolactin determination during the past several years. Since the blood was basically taken to examine the causes of hyperprolactinemia and only remained serum samples were used for this study, the Ethics Committee of Kobe City General Hospital judged that it was not required to obtain approval number.

Condition
Hyperprolactinemia

Study Type:	Observational
Study Design:	Observational Model: Defined Population Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Retrospective

Further study details as provided by Kansai Medical University:

Study Start Date:	January 2005
Estimated Study Completion Date:	December 2006

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Clinical diagnosis of hyperprolactinemia

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00436111

Locations

Japan
Kansai Medical University
Osaka, Japan, 570-8506

Sponsors and Collaborators

Kansai Medical University

Investigators

Study Chair:

Naoki Hattori, M.D., Ph.D.

Department of Pharmacology, Kansai Medical University

More Information

Publications:

Hattori N, Nakayama Y, Kitagawa K, Ishihara T, Saiki Y, Inagaki C. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol. 2006 Aug;190(2):287-93.

Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metab. 2005 May;90(5):3036-44. Epub 2005 Feb 1.

Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab. 1997 Sep;82(9):3107-10.

Hattori N, Ishihara T, Ikekubo K, Moridera K, Hino M, Kurahachi H. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992 Nov;75(5):1226-9.

ClinicalTrials.gov Identifier:	NCT00436111 History of Changes
Other Study ID Numbers:	KK-2007-1
Study First Received:	February 15, 2007
Last Updated:	February 15, 2007
Health Authority:	Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Kansai Medical University:

hyperprolactinemia
autoantibody

Additional relevant MeSH terms:

Hyperprolactinemia
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases

Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 21, 2013

To Top